Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Toshihisa Arai"'
1
Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study
Autor: Toshihisa Arai, Hiroyuki Ohbayashi, Kai Shibata, Yasuhiro Setoguchi, Yoshinosuke Fukuchi, Yukinori Sakata
Publikováno v: Pulmonary Pharmacology & Therapeutics. 37:73-80
Background Mucolytic agents are often used in Japan to ease excessive mucus production in patients with chronic obstructive pulmonary disease (COPD) or bronchial asthma (BA); the treatment ameliorates dyspnea and improves quality of life (QOL). Aim E
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fce59161a7971a144a4d903a33fee55
https://doi.org/10.1016/j.pupt.2016.03.001
Zobrazit plný text záznamu
2
A Multicenter Prospective Observational Study of Triple Therapy with Rabeprazole, Amoxicillin and Metronidazole for Helicobacter pylori in Japan
Autor: Norio Iinuma, Yukinori Sakata, Yoshinori Furuhata, Hitoshi Suzuki, Katsuya Sugizaki, Toshihisa Arai
Publikováno v: Internal Medicine. 51:3103-3108
Objective Triple therapy with rabeprazole (RPZ), amoxicillin (AMPC) and metronidazole (MNZ) (RPZ+AMPC+MNZ therapy: RAM therapy) has been approved by the Japanese Ministry of Health, Labour and Welfare as a second-line therapy for Helicobacter pylori-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1f1009e2c084fc74eb13b05a2fecf8c
https://doi.org/10.2169/internalmedicine.51.8510
Zobrazit plný text záznamu
3
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study
Autor: Masakazu Ichinose, Yoshinosuke Fukuchi, Hiromasa Inoue, Toshihisa Arai, Hideaki Miyagishi, Kai Shibata, Yukinori Sakata, Koichiro Tatsumi
Publikováno v: 5.1 Airway Pharmacology and Treatment.
Background /Aim: Lysozyme hydrochroride (mucopeptide N-acetyl muramyl hydrolase; LYS) is widely used as a mucolytic and anti-airway inflammatory agent in Japan. We evaluated the effects of long-term LYS administration on COPD exacerbation. Method: In
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::342f89bb83bbd160fa5f669ff8b4d6ef
https://doi.org/10.1183/13993003.congress-2015.pa4359
Zobrazit plný text záznamu
4
A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan
Autor: Katsuya, Sugizaki, Yukinori, Sakata, Toshihisa, Arai, Yoshinori, Furuhata, Norio, Iinuma, Hitoshi, Suzuki
Publikováno v: Internal medicine (Tokyo, Japan). 51(22)
Triple therapy with rabeprazole (RPZ), amoxicillin (AMPC) and metronidazole (MNZ) (RPZ+AMPC+MNZ therapy: RAM therapy) has been approved by the Japanese Ministry of Health, Labour and Welfare as a second-line therapy for Helicobacter pylori-positive g
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::51d513472dcc1760993a881c0e1e6ca7
https://pubmed.ncbi.nlm.nih.gov/23154713
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje